• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Schachner Holly Caren

    12/28/23 5:36:19 PM ET
    $AMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMTI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Schachner Holly Caren

    (Last) (First) (Middle)
    AMTI, C/O CORPORATION TRUST COMPANY,
    TRUST CENTER, 1209 ORANGE ST

    (Street)
    WILMINGTON DE 19801

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Applied Molecular Transport Inc. [ AMTI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/27/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $30.01 12/27/2023 D 38,976 (1) 08/23/2031 Common Stock 38,976 $0.00 0 D
    Stock Option (Right to Buy) $3.13 12/27/2023 D 20,000 (1) 05/24/2032 Common Stock 20,000 $0.00 0 D
    Stock Option (Right to Buy) $0.34 12/27/2023 D 20,000 (2) 06/14/2033 Common Stock 20,000 $0.00 0 D
    Explanation of Responses:
    1. Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
    2. Pursuant to the terms of the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.
    Remarks:
    /s/Brandon Hants Attorney-in-Fact for Holly C Schachner 12/28/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AMTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Applied Molecular with a new price target

      JMP Securities initiated coverage of Applied Molecular with a rating of Outperform and set a new price target of $92.00

      3/17/21 8:25:08 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Applied Molecular Transport with a new price target

      JMP Securities initiated coverage of Applied Molecular Transport with a rating of Mkt Outperform and set a new price target of $92.00

      3/17/21 7:32:06 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Applied Molecular Transport with a new price target

      SVB Leerink reiterated coverage of Applied Molecular Transport with a rating of Outperform and set a new price target of $74.00 from $32.00 previously

      2/25/21 10:32:42 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Epiq Capital Group, Llc disposed of 8,337,518 shares (SEC Form 4)

      4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

      12/29/23 5:40:35 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vandevender Aaron returned 212,659 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

      12/28/23 5:39:57 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Smither John W

      4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

      12/28/23 5:38:19 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

      Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (NASDAQ:AMTI) ("AMT"), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therape

      12/27/23 4:15:00 PM ET
      $AMTI
      $CYTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

      Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport, Inc. ("AMT") on track to close before year end Company continues to bolster cash position to extend runway through clinical and regulatory milestones Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023. "Our number one priority remains to

      11/15/23 8:05:00 AM ET
      $AMTI
      $CYTH
      $RFL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Real Estate
    • Applied Molecular Transport Reports Third Quarter 2023 Financial Results

      Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive merger agreement with Cyclo Therapeutics Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)The merger is expected to close by year end 20

      11/9/23 4:01:00 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Financials

    Live finance-specific insights

    See more

    $AMTI
    SEC Filings

    See more

    $AMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AMTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

      – Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 – Post hoc analysis of patients with shorter duration of ulcerative colitis (UC) < 5 years showed clinical remission rate of 43.8% (7/16) in patients receiving combination versus 15.4% (2/13) in patients receiving adalimumab alone, suggesting combination treatment earlier in the course of disease may be beneficial – AMT-101 appeared safe and well-tolerated – Company will host live conference call and webcast today, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., July 06

      7/6/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

      SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast InformationTo join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and

      7/5/22 4:01:00 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

      –  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)–  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile–  Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups–  Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis–  Further substantiates potential of AMT-101 and Company's oral biologics platform–  Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Appli

      4/25/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Applied Molecular Transport Inc.

      15-12G - Applied Molecular Transport Inc. (0001801777) (Filer)

      1/9/24 6:12:27 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Applied Molecular Transport Inc.

      EFFECT - Applied Molecular Transport Inc. (0001801777) (Filer)

      1/3/24 12:15:07 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by Applied Molecular Transport Inc.

      POSASR - Applied Molecular Transport Inc. (0001801777) (Filer)

      1/2/24 9:15:36 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Applied Molecular Transport Inc. (Amendment)

      SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)

      2/14/24 4:24:03 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Applied Molecular Transport Inc. (Amendment)

      SC 13D/A - Applied Molecular Transport Inc. (0001801777) (Subject)

      1/5/24 4:18:22 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Applied Molecular Transport Inc. (Amendment)

      SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)

      2/9/23 4:05:59 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. "We were pleased to recently announce positive top-line data from our FILLMORE trial in chronic pou

      5/9/22 4:01:00 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport Appoints Charlene Banard to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard is an accomplished biopharmaceutical executive with over 30 years of experience leading global technical operations and quality organizations within the life sciences industry. Ms. Banard will also become a member of the company's Audit Committee. "Charlene is a welcome addition to AMT's Board of Directors, bringing critical technical operations expertise and a strong strategic vision to the organization," said Tahir Mahmood, Ph.D.,

      4/6/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs

      Company continues to strengthen key functions and corporate leadership Company on track to announce top-line data from four ongoing oral AMT-101 Phase 2 trials in 2022 SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn Finkle as senior vice president, head of regulatory affairs. She becomes a member of the AMT executive leadership team, reporting to chief executive officer and co-founder of AMT, Tahir Mahmood, Ph.D. "We are thrilled to welcome Carolyn as the newest member of the executive leadership team at AMT," said Dr. Mahmood. "Car

      3/14/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care